Rep. Marjorie Taylor Greene Buys Merck & Co., Inc. (NYSE:MRK) Stock

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Merck & Co., Inc. (NYSE:MRK). In a filing disclosed on April 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in Merck & Co., Inc. stock on April 9th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Apple (NASDAQ:AAPL) on 4/9/2025.
• Purchased $1,001 – $15,000 in shares of Cummins (NYSE:CMI) on 4/9/2025.
• Purchased $1,001 – $15,000 in shares of Advanced Micro Devices (NASDAQ:AMD) on 4/9/2025.
• Purchased $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 4/9/2025.
• Purchased $1,001 – $15,000 in shares of Applied Materials (NASDAQ:AMAT) on 4/9/2025.
• Purchased $1,001 – $15,000 in shares of ASML (NASDAQ:ASML) on 4/9/2025.
• Purchased $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 4/9/2025.
• Purchased $1,001 – $15,000 in shares of Devon Energy (NYSE:DVN) on 4/9/2025.
• Purchased $1,001 – $15,000 in shares of Palantir Technologies (NASDAQ:PLTR) on 4/9/2025.
• Purchased $1,001 – $15,000 in shares of Lululemon Athletica (NASDAQ:LULU) on 4/8/2025.

Merck & Co., Inc. Price Performance

NYSE:MRK opened at $79.00 on Tuesday. The firm’s fifty day moving average is $88.22 and its two-hundred day moving average is $97.04. The firm has a market cap of $199.56 billion, a price-to-earnings ratio of 11.74, a PEG ratio of 0.77 and a beta of 0.40. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36. Merck & Co., Inc. has a one year low of $75.96 and a one year high of $134.63.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, February 4th. The company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.85 by ($0.13). The company had revenue of $15.62 billion during the quarter, compared to analysts’ expectations of $15.51 billion. Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.03 EPS. Research analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. declared that its board has initiated a share repurchase plan on Tuesday, January 28th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the company to repurchase up to 4.1% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 7th. Stockholders of record on Monday, March 17th were paid a $0.81 dividend. The ex-dividend date of this dividend was Monday, March 17th. This represents a $3.24 dividend on an annualized basis and a dividend yield of 4.10%. Merck & Co., Inc.’s payout ratio is currently 48.14%.

Hedge Funds Weigh In On Merck & Co., Inc.

Several institutional investors and hedge funds have recently bought and sold shares of the company. CGN Advisors LLC boosted its stake in Merck & Co., Inc. by 0.4% in the fourth quarter. CGN Advisors LLC now owns 26,969 shares of the company’s stock valued at $2,683,000 after acquiring an additional 102 shares during the period. Cypress Wealth Services LLC lifted its holdings in shares of Merck & Co., Inc. by 3.1% in the 4th quarter. Cypress Wealth Services LLC now owns 3,639 shares of the company’s stock worth $362,000 after purchasing an additional 111 shares during the last quarter. TI Trust Inc. lifted its holdings in shares of Merck & Co., Inc. by 0.6% in the 4th quarter. TI Trust Inc. now owns 19,834 shares of the company’s stock worth $1,973,000 after purchasing an additional 111 shares during the last quarter. Hengehold Capital Management LLC boosted its position in Merck & Co., Inc. by 0.3% during the 4th quarter. Hengehold Capital Management LLC now owns 39,989 shares of the company’s stock valued at $3,978,000 after purchasing an additional 112 shares during the period. Finally, Peterson Wealth Services grew its stake in Merck & Co., Inc. by 0.5% during the 4th quarter. Peterson Wealth Services now owns 21,479 shares of the company’s stock worth $2,137,000 after buying an additional 113 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on MRK. BMO Capital Markets cut their target price on shares of Merck & Co., Inc. from $105.00 to $96.00 and set a “market perform” rating for the company in a report on Wednesday, February 5th. Guggenheim lowered their target price on shares of Merck & Co., Inc. from $122.00 to $115.00 and set a “buy” rating on the stock in a research note on Wednesday, February 12th. UBS Group dropped their target price on Merck & Co., Inc. from $125.00 to $120.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Morgan Stanley lowered their price target on Merck & Co., Inc. from $113.00 to $106.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. Finally, Bank of America reduced their price target on shares of Merck & Co., Inc. from $118.00 to $112.00 and set a “buy” rating for the company in a research report on Wednesday, February 5th. Eleven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average target price of $115.50.

Insider Buying and Selling

In other Merck & Co., Inc. news, insider Cristal N. Downing sold 2,361 shares of the business’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $88.76, for a total transaction of $209,562.36. Following the completion of the transaction, the insider now directly owns 7,085 shares of the company’s stock, valued at $628,864.60. The trade was a 24.99 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Inge G. Thulin purchased 2,833 shares of the company’s stock in a transaction on Thursday, February 6th. The stock was purchased at an average price of $88.25 per share, for a total transaction of $250,012.25. Following the purchase, the director now directly owns 2,933 shares of the company’s stock, valued at $258,837.25. This trade represents a 2,833.00 % increase in their position. The disclosure for this purchase can be found here. 0.09% of the stock is owned by company insiders.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia’s 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia’s 14th Congressional District. She declared candidacy for the 2026 election.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.